CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Enoxaparin 1 mg/kgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1447 Unfractionated heparin SC Wiki 1.00
drug1445 Unfractionated Heparin IV Wiki 1.00
drug474 Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki 1.00
drug331 Clopidogrel Wiki 0.71

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D054556 Venous Thromboembolism NIH 0.45
D013923 Thromboembolism NIH 0.33
D013927 Thrombosis NIH 0.28

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.

NCT04409834 COVID-19 Venous Thromboembolism Arterial Thrombosis Drug: Unfractionated Heparin IV Drug: Enoxaparin 1 mg/kg Drug: Clopidogrel Drug: Unfractionated heparin SC Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
MeSH:Thrombosis Thromboembolism Venous Thromboembolism
HPO:Thromboembolism

Primary Outcomes

Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT

Measure: Primary endpoint: Venous or arterial thrombotic events

Time: 28 days or until hospital discharge, whichever earlier

Secondary Outcomes

Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia

Measure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events

Time: 28 days or until hospital discharge, whichever earlier

Related HPO nodes (Using clinical trials)

HP:0001907: Thromboembolism
Genes 22
MTRR F13A1 KCNQ1 PIEZO1 INHBA PIGA HABP2 FCGR2C CBS SERPINC1 F2 PRKAR1A HRG MMACHC PRDX1 ADA2 JAK2 CYTB EPOR SLC4A1 MTHFR KCNN4
Protein Mutations 3
G20210A G21210A R506Q
SNP 7
rs10276036 rs1128503 rs1202167 rs1202168 rs1202169 rs2235046 rs4148738